CDK9 and prostate cancer: Indeed, treatment of prostate cancer cells with the highly specific CDK9 inhibitor NVP2, or a structurally unrelated CDK9 inhibitor AT7519, induced accumulation of the DNA damage response marker p-H2AX (Fig. 4B and Additional file 1: Fig. S5A).